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Vaginal microbiota and human papillomavirus infection
among young Swedish women
Liqin Cheng1,5, Johanna Norenhag2,5, Yue O. O. Hu 1,5, Nele Brusselaers1, Emma Fransson 1,2, Andreas Ährlund-Richter3,
Unnur Guðnadóttir1, Pia Angelidou1, Yinghua Zha1, Marica Hamsten1, Ina Schuppe-Koistinen1,4, Matts Olovsson2,
Lars Engstrand1,4 and Juan Du 1✉
Human papillomavirus (HPV) infection is one of the most common sexually transmitted diseases. To define the HPV-associated
microbial community among a high vaccination coverage population, we carried out a cross-sectional study with 345 young
Swedish women. The microbial composition and its association with HPV infection, including 27 HPV types, were analyzed.
Microbial alpha-diversity was found significantly higher in the HPV-infected group (especially with oncogenic HPV types and
multiple HPV types), compared with the HPV negative group. The vaginal microbiota among HPV-infected women was
characterized by a larger number of bacterial vaginosis-associated bacteria (BVAB), Sneathia, Prevotella, and Megasphaera. In
addition, the correlation analysis demonstrated that twice as many women with non-Lactobacillus-dominant vaginal microbiota
were infected with oncogenic HPV types, compared with L. crispatus-dominated vaginal microbiota. The data suggest that HPV
infection, especially oncogenic HPV types, is strongly associated with a non-Lactobacillus-dominant vaginal microbiota, regardless
of age and vaccination status.
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INTRODUCTION
Infection with human papillomavirus (HPV) is among the most
common sexually transmitted diseases in the world, with the
highest prevalence among women below 251,2. HPV infection is
the main cause of cervical cancer and is related to many other
cancers, including head and neck cancer3. Depending on their
oncogenic potential, mucosal HPV types can be divided into
oncogenic HPVs, such as those observed in cancer cases, and non-
oncogenic HPVs, mainly found in condyloma4. The two most
common HPV types in cervical cancer are HPV16 and 18, which are
responsible for ~70% of cervical cancer cases worldwide5,6. At a
youth clinic in Stockholm, Sweden, we have previously shown an
overall cervical HPV prevalence of over 70% among young girls in
Sweden7–9. The HPV vaccination program was gradually intro-
duced to Sweden from 2007. Since 2012, all girls between the
ages of 10 and 12 years are offered free vaccination with the
quadrivalent Gardasil vaccine against HPV6, 11, 16, and 18, in a
school-based vaccination program and catch-up vaccination. The
vaccination ratio has increased dramatically from 10.7%
(2008–2010) to 82.1% (2017–2018)7. The prevalence of HPV types
covered in the vaccine has dropped significantly in vaccinated
women compared with non-vaccinated women, underlining the
importance and success of the vaccination program7,8. However,
the total HPV prevalence caused by HPV types that are not
covered by the vaccine is still high, indicating that more
interventions to reduce these HPV infections are still needed7,8.
Further, the influence of the HPV vaccine on vaginal microbiota
has not been thoroughly investigated, especially in a high
vaccination coverage country.
An increasing number of studies suggest that vaginal micro-
biota play an essential role in women’s health, specifically in
sexually transmitted diseases, pelvic inflammatory disease, and
adverse obstetric outcomes10–13. The vaginal microbiota is
primarily dominated by one of the four most common Lactoba-
cillus species: Lactobacillus crispatus, Lactobacillus iners, Lactoba-
cillus gasseri, and Lactobacillus jensenii14–16. In addition, some
women may have vaginal microbiota dominated by bacterial
species other than Lactobacilli, such as Prevotella, Gardnerella, and
Sneathia11,17,18. The general clinical diagnostic approaches world-
wide for bacterial vaginosis (BV), which is also characterized by a
lack of Lactobacilli but a higher quantity of aerobic and anaerobic
bacteria, are the Amsel criteria and the Nugent score, based on
wet smear diagnosis and Gram staining. However, the sensitivity
and specificity for both methods are moderate19. Molecular
diagnosis, such as 16S rRNA gene sequencing, enables the
microbiota determination at the species level. Bacterial vaginosis
associated bacteria (BVAB), including BVAB 1, 2, and 3, have been
identified from the vaginal fluid of women with bacterial vaginosis
and could serve as potential vaginosis biomarkers20–22. Unfortu-
nately, BVAB have not been included in the 16S amplicon
sequencing-based vaginal microbiota studies related to HPV,
probably due to taxonomic information missing from the popular
16S rRNA databases, with most studies on BVAB being based on
qPCR sequencing.
Cross-sectional studies and very few longitudinal studies from
other countries showed that L. crispatus is observed more
frequently in women without HPV infection and cancer lesions,
whereas L. iners and non-Lactobacillus species are more common
in HPV-infected women and patients with cancer lesions23–26.
However, there are no data available yet in the Nordic countries
on the vaginal microbiota composition and its relationship with
HPV infection, using a sequencing method. Thus, we initiated a
cross-sectional study to assess the association between the
vaginal microbiota and 27 HPV types in Sweden. In addition,
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because HPV infection has the highest prevalence among young
women, we designed our study to focus on women below 30
years old.
RESULTS
Participant characteristics in the study cohort
As seen from the flowchart of Supplementary Fig. 1, a total of 345
participants were enrolled in this study, in which 33 women were
excluded from the study due to antibiotics usage within the past
three months (n= 18) or incomplete clinical information (n= 15).
Samples with low DNA concentration and low reads in sequencing
(n= 55) were excluded from downstream microbiota analysis.
Eventually, 169 samples from women visiting the youth clinic and
88 samples from women attending the cervical screening were
included for analyses (Supplementary Fig. 1).
The HPV prevalence of the samples from the youth clinic have
been published previously7. From the 169 women visiting the
youth clinic, the prevalence of any HPV and oncogenic HPV were
67.5% and 59.8%, respectively (Supplementary Table 1). Among
the 88 participants attending the cervical screening, the overall
HPV prevalence was 34.1%, with HPV56 (6.8%), HPV45 (4.5%), and
HPV52 (4.5%) as the three most common oncogenic HPV types
(Supplementary Fig. 2a and Supplementary Table 1). The HPV
vaccine appeared to provide full protection to the participants in
the cervical screening, with no one (including the non-vaccinated
ones) being infected with the HPV types covered in the
quadrivalent HPV vaccine (Supplementary Fig. 2a, b). Moreover,
when compared vaccinated with non-vaccinated women, none of
the prevalence difference (any HPV, oncogenic HPVs, HPV covered
in vaccine, probably oncogenic HPVs, and non-oncogenic HPVs)
reached statistical significance according to Fisher’s exact test
(Supplementary Fig. 2b). Both the HPV infection prevalence and
vaccine coverage in the cervical screening samples were
significantly lower than that of the youth clinic samples (34.1%
vs. 67.5%, p < 0.0001 and 61.4% vs. 81.1%, p < 0.001, respectively;
Figs. 1a, b and Supplementary Table 1).
Vaginal microbiota was comparable in women from the youth
clinic and the cervical screening
We continued to compare the microbial community composition
from the two sources. Alpha diversity analysis of the microbiota
profile based on Shannon and Faith’s diversity suggested no
significant difference between the two sources (p= 0.064 and
0.138, respectively), while Chao 1 analysis showed a significant
difference between the two sources (p= 0.004; Fig. 1c and
Supplementary Figs. 3a and 4a). The bacterial community profiles
in the samples from the youth clinic and the cervical screening
samples were comparable, with overall 32.7% L. crispatus
dominated, 30.4% L. iners dominated, and 33.5% non-Lactoba-
cillus-dominated (Supplementary Table 1). Furthermore, no
significant difference was observed in the ratio of the four
community types based on sample source (Supplementary Table
2). In order to address the relationship between vaginal
microbiota and HPV infection, we combined the samples from
the youth clinic and the cervical screening for all the following
analysis.
Principal coordinates analysis (PCoA) based on the Bray-Curtis
distance demonstrated that all the samples were mainly separated
into L. crispatus-, L. iners-, and non-Lactobacillus-dominated cate-
gories, and only a few samples were dominated by other
Lactobacillus species (Fig. 1d). Detail distributions of the amplicon
sequence variants (ASVs) from the major genera and species
including Gardnerella, Prevotella, Sneathia, and BVABs were shown
in Supplementary Fig. 5a. Furthermore, we also performed the PCoA
based on the UniFrac phylogenetic distance, which separated all the
samples into Lactobacillus-dominated and non-Lactobacillus-domi-
nated categories (Supplementary Fig. 6a). Since Lactobacillus species
are phylogenetically close, Lactobacillus-dominated samples clus-



































































Fig. 1 Comparison of HPV prevalence, HPV vaccination status, and microbial diversity in the youth clinic and the cervical screening
samples. a Significantly higher HPV prevalence was observed from the youth clinic samples than the cervical screening samples.
b Significantly higher HPV vaccination coverage was shown in samples from the youth clinic than samples from the cervical screening.
c Microbial alpha diversity based on Shannon analysis did not show the difference between samples from the youth clinic and the cervical
screening. Every dot in the violin plot represents one individual. Data were presented as mean values with standard deviations. d Principal
coordinates analysis (PCoA) of microbial species data based on Bray-Curtis distance matrix demonstrated three main vaginal microbiota
clusters. Statistical significance between the groups was tested by Fisher’s exact test in a and b, and by Wilcoxon rank-sum one-sided test in
c (p= 0.108). ***p < 0.001 and ****p < 0.0001. HPV+: HPV-infected, HPV−: HPV-uninfected.
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Fig. 6a). The contributions of the ASVs from the major genera and
species were presented in the separated PCoA panels of Supple-
mentary Fig. 6b.
Young women with HPV infection had higher vaginal microbial
diversity
In general, L. crispatus and L. iners were found to be the most
dominant species among both HPV-uninfected and HPV-infected
participants (Fig. 2a, b). The majority of non-Lactobacillus-
dominated samples consisted of a large proportion of bacteria
belonging to the genera Gardnerella, Prevotella, Sneathia, and
BVABs (Fig. 2a, b). The Shannon, Chao 1, and Faith’s diversity
analyses all found significantly higher microbial alpha diversity
among HPV-infected women than those without HPV infection
(p= 0.0006, 0.001, and 0.0005, respectively; Fig. 2c and Supple-
mentary Figs. 3b and 4b). The ratios of the four vaginal microbiota
compositions were significantly different between women with
and without HPV infection (p= 0.043) (Supplementary Table 2).
Notably, the non-Lactobacillus community profile was more
prevalent among HPV-infected women, compared with unin-
fected women according to Fisher’s exact test (p= 0.011; Fig. 2a, b
and Supplementary Table 2). However, the PCoA analysis based
on the Bray–Curtis distance showed no clear separation between
HPV-uninfected and HPV-infected groups based on their microbial
community compositions (Supplementary Fig. 5b). The PCoA




Fig. 2 Difference in vaginal microbiota of HPV-uninfected and HPV-infected young women. a Vaginal microbiota at the genus/species level
from HPV-uninfected young women. Except BVABs, the following criteria were used in order to show the important and abundant taxa clearly:
(1) Bacteria with over 1% mean relative abundance in all the samples. (2) Lactobacillus species that have more than 10% of reads in any sample.
(3) Non-Lactobacillus genera that have over 30% of reads in any sample. b Vaginal microbiota at genus/species level from HPV-infected young
women. Same criteria were used as in a. c Microbial alpha diversity (Shannon) comparison between groups of HPV-uninfected and HPV-
infected young women demonstrated a significantly higher vaginal microbiota diversity among HPV-infected women by Wilcoxon rank-sum
one-sided test. Data were presented as mean values with standard deviations. ***p < 0.001. HPV+: HPV-infected, HPV−: HPV-uninfected.
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the samples according to HPV infection status (Supplementary
Fig. 6c).
Young women with oncogenic HPV infection had higher vaginal
microbial diversity
Microbial alpha diversity based on Shannon, Chao 1, and Faith’s
diversity analyses displayed significantly higher diversity of
women infected with both oncogenic and non-oncogenic HPVs,
than HPV-uninfected women (p= 0.00008, 0.0002, and 0.0005,
respectively; Fig. 3a and Supplementary Figs. 3c and 4c). The same
holds true when comparing women with only oncogenic HPV
infection with those without HPV infection (p= 0.041, 0.030, and
0.025, respectively; Fig. 3a and Supplementary Figs. 3c and 4c).
Shannon and Faith’s diversity analyses also displayed significant
differences between women infected with both oncogenic and
non-oncogenic HPV, and women with only oncogenic HPV
infection (p= 0.013 and 0.03, respectively), but no significant
difference among other groups was observed. The PCoA analysis
showed no clear separation of samples with HPV-uninfected,
infected with both oncogenic and non-oncogenic HPVs, and only
oncogenic HPVs (Supplementary Figs. 5c, d and 6d). We further
divided samples according to their HPV phylogenetic groups and
evaluated the association of HPVs phylogenetic groups with
vaginal microbiome composition. However, PCoA based on the
UniFrac phylogenetic distance showed no clear separation among
samples from different HPV phylogenetic groups either (Supple-
mentary Fig. 6e).
Young women with multiple HPV types had higher vaginal
microbial diversity
We further analyzed whether the number of infected HPV types
affected vaginal microbial diversity. Compared with women
without HPV infection, all the analyses showed that women
infected with multiple HPV types had significantly higher
microbiota diversity (p= 0.0004 for Shannon, 0.0007 for Chao 1,
and 0.0008 for Faith’s diversity, respectively; Fig. 3b and
Supplementary Figs. 3d and 4d). Only the Shannon analysis
displayed significantly higher microbiota diversity in women
infected with single HPV type than in women without HPV
infection (p= 0.042; Fig. 3b and Supplementary Figs. 3d and 4d).
Young women with certain HPV types had higher microbial
diversity
Detailed information on 27 HPV types allowed us to compare the
vaginal microbiome from participants infected with different HPV
types. As listed in Fig. 3c, among the HPV types with enough
women in the group for analysis (n > 5), women infected with
HPV39, 42, and 56 had significantly higher diversity compared
with HPV-uninfected group in the Shannon analysis, which
indicates that infection by these three HPV types tends to be
related to higher diversity in vaginal microbiota (Fig. 3c). HPV39
and 58 in the Chao 1 analysis and HPV39, 58, and 59 in the Faith’s
diversity analysis were the HPV types showing significantly higher
diversity compared with the HPV-uninfected group (Supplemen-
tary Figs. 3e and 4e).
Certain bacterial species were related to HPV infection
To identify potential bacterial biomarkers for HPV infection, we
compared the relative abundance of all the bacteria from women
with and without HPV infection. From statistical analysis on
microbiota taxonomy, we observed that BVAB 1, BVAB 2, Sneathia,
Prevotella, and Megasphaera were significantly more prevalent
among HPV-infected women than HPV-uninfected women (q=
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Fig. 3 Microbial alpha diversity analysis based on Shannon index according to HPV oncogenic type, infected numbers and HPV types.
a Microbiota diversity of participant group of uninfected women, and the groups infected with oncogenic plus non-oncogenic HPVs,
oncogenic HPVs, non-oncogenic HPVs and probably oncogenic HPVs were compared. The five groups showed significantly different diversity
(Kruskal–Wallis test; p < 0.05). Groups with oncogenic plus non-oncogenic HPVs and oncogenic HPVs showed statistical higher diversity
compared with HPV-uninfected group (Wilcoxon one-side test; *p < 0.05 and ****p < 0.0001). b Microbiota diversity comparison of HPV-
uninfected group, and groups infected with single and multiple HPV types. The diversities are significantly different among the three groups
(Kruskal–Wallis test; p < 0.005). Significant higher microbiota diversity of participants infected with single and multiple HPV types was
observed compared with HPV-uninfected women (Wilcoxon one-side test; *p < 0.05, ***p < 0.001). c Microbiota diversity among participants
infected with different HPV types in comparison with uninfected women. Significantly higher microbiota diversity was observed with women
infected with HPV39, 56, and 42, compared with uninfected women. Statistical significance between the groups was tested by Wilcoxon one-
side test adjusted by Benjamini–Hochberg correction. (*q < 0.05). Data was presented as mean values with standard deviations. HPV−: HPV-
uninfected, O-HPV: oncogenic HPV, NO-HPV: non-oncogenic HPV, PO-HPV: probably oncogenic HPV.
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Interestingly, BVAB 1 almost exclusively presented in the vaginal
microbiota of HPV-infected young women, indicating a very close
relationship between BVAB 1 and HPV infection (Fig. 2a, 2b).
Age and HPV vaccine had little influence on vaginal microbial
diversity
In general, HPV vaccine coverage declined with increasing age,
probably due to the lag time of the national HPV vaccination
program in Sweden. Vaccination coverage dropped from 100%
among young women age 14–17 to 70–90% among those age
18–24, and 20–60% among those age 25–29 (Fig. 5a). Irrespective
of vaccination status, HPV prevalence increased from age 14 (0%),
and peaked around the age of 18-26 (~50% and above) and
dropped to ~10% at age of 29 (Fig. 5b). Oncogenic HPV types
accounted for most of the HPV-infected cases in each age group
and followed similar trend as the total HPV infection (Fig. 5b)7.
However, the vaginal microbiota diversity analysis according to
age showed no difference among the age groups in all three
analysis (Fig. 5c and Supplementary Figs. 3f and 4f). Similarly,
microbial alpha diversity of vaccinated women also showed no
significant difference from non-vaccinated women (Fig. 5d and
Supplementary Figs. 3g and 4g). In addition, these data were
supported by no significant difference was shown in the ratio of
the four community types among samples with different age and
vaccine status (Supplementary Table 2). All together, these data
suggested that age and HPV vaccine status had little influence on
microbial composition.
Age, vaccine status, and vaginal microbiota showed correlation to
HPV infection
We continued to evaluate the correlation of age, vaccination
status, and vaginal microbiota with the risk of HPV or oncogenic
HPV infection. The significantly higher HPV prevalence in the
youth clinic compared with the cervical screening samples,
contributed to the highest ratio of any HPV, oncogenic HPV, or
multi-type HPV infection observed among the 19–24 age group
(Table 1 and Supplementary Table 3). HPV vaccination demon-
strated a significant protective effect against multiple HPV
infection (p < 0.001, Supplementary Table 3).
Logistic regression analysis showed that age and the sample
source were significantly associated with the risk of being HPV-
infected. The highest HPV risks after adjustment were among
women in the 19–24 age group (odds ratios: OR= 4.0, 95%
confidence intervals: CI 1.9–8.7), compared with women below 18,
and women from the youth clinic (OR= 5.4, 95% 2.4–12.2),
compared with the cervical screening samples (Table 1). Similar
associations were observed for both oncogenic HPV and non-
oncogenic HPV types. After adjustment for the other variables, age
(19–24 years old) and sample source (youth clinic), and non-
Lactobacillus dominated remained significantly associated with
infections with oncogenic HPV, multiple HPV, and multiple
oncogenic HPV (Table 1 and Supplementary Table 3). Moreover,
HPV vaccine halved the risk of oncogenic HPV infection (OR= 0.5,
95% CI 0.2–1.00) (Table 1 and Supplementary Table 3).
Non-Lactobacillus-dominated vaginal microbiota showed more
than twice the risk of having an infection with any HPV, oncogenic
HPV, and non-oncogenic HPV infection than those with L.
crispatus-dominated microbiota (OR= 2.0, 95% CI 1.1–3.7 for
HPV infection; OR= 2.1, 95% CI 1.2–4.0 for oncogenic HPV
infection; and OR= 2.2, 95% CI 1.1–4.8 for non-oncogenic HPV
infection). After adjustment for the other variables listed in the
table, the risk of oncogenic HPV infection was OR= 2.0 (95% CI
1.0–3.9) in non-Lactobacillus-dominated samples, compared with
L. crispatus-dominated samples. The difference became more







































































Fig. 4 Bacterial species/genera presented significantly different in HPV-infected and HPV-uninfected women. BVAB1, BVAB2, Sneathia,
Prevotella, and Megasphaera were the bacterial species/genera that significantly higher presented in HPV-infected women than HPV-
uninfected women. Analysis only conducted on the taxa listed in Fig. 2. Statistical significance between the groups was tested by two-sided
Wilcoxon rank-sum test adjusted by Benjamini–Hochberg correction. *q < 0.05, **q < 0.01. Data was presented as median values with the
interquartile and upper adjacent values indicated by the thick and thin lines, separately. HPV+: HPV-infected, HPV−: HPV-uninfected.
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oncogenic HPV types were included in the analysis (OR= 2.5, 95%
CI 1.1–5.9 for multiple HPV infection; OR= 2.4, 95% CI 1.0–5.8 for
multiple oncogenic HPV infection; Table 1 and Supplementary
Table 3).
DISCUSSION
This is a large cross-sectional study for evaluating the relationship
between vaginal microbiota and HPV infection. It is also the study
carried out in a high HPV vaccine coverage country with young
women, using sequencing technology. This study brings essential
comparable data and a geographic contribution to the worldwide
vaginal microbiome researches. Overall, a significantly higher
microbiota diversity was observed in women infected with any
HPV, oncogenic HPV, and multiple HPV types, than in women not
infected with HPV (Table 1 and Fig. 3a, b). Further, we also
demonstrated a slight but significantly increased microbiota
diversity among women infected with oncogenic HPV39 and 56
(Fig. 3c). We suggest that BVABs, which have not been studied in
previous HPV-related studies, together with Sneathia, Prevotella,
and Megasphaera, are associated with HPV infection. Lastly, HPV
vaccination showed a strong protective effect against the HPV
types covered in the current vaccination program, without any
perceptible influence on the vaginal microbiota.
Our recently-published meta-analysis showed that vaginal
microbiota dominated by non-Lactobacillus species or L. iners
have a stronger association with HPV infection and dysplasia,
compared with L. crispatus24. In this study, the correlation of
different vaginal microbiota compositions and their relation to
HPV infection was analyzed, highlighting the different infection
risks posed by the various vaginal microbiota profiles (Figs. 2, 3
and Table 1). Similar to the findings in our meta-analysis, this study
also showed that the non-Lactobacillus vaginal microbiota profile
was more common among women with infections due to any
HPV, oncogenic HPV, and multiple HPV types (Figs. 2, 3 and Table 1).
Nearly all the major species from the non-Lactobacillus-dominant
group were found in significantly higher amounts in the HPV-
infected group, compared with the HPV-uninfected group. Our
data are in line with other studies and suggest that several non-
Lactobacillus species could be used as potential biomarkers for
HPV infection12,27. We did not find clear separation of vaginal
microbiota in different HPV oncogenic potential groups, nor in
HPV phylogenetic groups, which indicates a complicated interac-
tion between HPV and vaginal microbiota.
Vaginal microbial community-state type has been used to
classify the vaginal microbiota by several previous studies14,16,17,27.
However, our study, together with other recently-published data
on the vaginal microbiome, demonstrated that the majority of
vaginal microbiota samples are dominated either by L. crispatus or
L. iners, and individuals with a low-Lactobacillus vaginal microbial
community, which are commonly colonized by bacteria such as
Gardnerella, Prevotella, Sneathia, and BVABs17,18,28. Considering the
proportion of low-Lactobacillus cases, more detailed community
state types of bacteria other than Lactobacilli may be useful for
vaginal microbiome research. Notably, in our study, we collected
all published BVAB-related sequences and identified them from
the ASVs, while the identifications were validated with BVAB qPCR
primers. The total prevalence of BVAB in our study is comparable
to those found in the human microbiome project11,18. The high
prevalence of BVAB 1 in HPV-positive women indicates a potential
bacterial vaginosis condition in HPV-infected young women and
probably a non-vaginosis condition in HPV-uninfected young
women with the non-Lactobacillus dominated vaginal microbiota.
In addition, similar to other studies, we found a strong relationship
between HPV infection and enrichment of bacteria, including
Sneathia, which correlates with cervical neoplasm, and Prevotella,
which contributes to HPV persistent infection25,29,30.
Vaccination status showed no influence on vaginal microbiota.
However, this study revealed its strong protection against HPV
infection, especially against infection with multiple HPV types,
demonstrating the success of the Swedish national HPV vaccine
program (Table 1 and Supplementary Table 3)7–9. Nevertheless, we
found that women in the age group 19–24 had the highest risk of
being infected with any HPV, oncogenic HPV, or multiple HPV
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Fig. 5 HPV infection and microbiota diversity based on HPV vaccination status and age. a HPV vaccination status in all the samples
showed a decreased trend in vaccination coverage as age increased. b HPV prevalence and oncogenic HPV prevalence in all samples
according to age. An overall high HPV prevalence was observed between age of 18–26. Most of the HPV infection contained oncogenic HPV in
all the age groups. c Microbial alpha diversity based on Shannon index of all the samples showed no significant difference among age groups
(Kruskal–Wallis test; p > 0.05). d Microbial alpha diversity based on Shannon index of all the samples did not show significant difference
between the groups with and without vaccination (Wilcoxon rank-sum one-sided test; p > 0.05). Data were presented as mean values with
standard deviations.
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types (Table 1 and Supplementary Table 3). The high HPV infection
rate is mainly caused by HPV types that are not covered in the
vaccine7. So, although the vaccination coverage is over 80%
among the youth clinic participants, the HPV infection rate in this
group is still high. Another possible reason is probably due to
nearly all the samples from women below 23 being from the
youth clinic, frequented by women seeking advice on birth control
or sexually transmitted diseases7–9. This analysis may therefore be
considered biased towards sexually active young women with
possible symptoms of sexually transmitted diseases. This is also
supported by the significantly higher HPV prevalence among the
youth clinic participants than the older cervical screening
participants (Supplementary Table 1). Notably, although sample
source, age, and vaccination status affected the HPV infection
status (Figs. 1, 5 and Supplementary Figs. 3 and 4), these factors
did not seem to contribute to variability in the vaginal microbiota.
This ruled out the confounders for microbiota analysis related to
HPV infection and suggested that the relationship between HPV
infection and vaginal microbiota is solid (Table 1, Fig. 2 and
Supplementary Figs. 3 and 4).
Current studies on the association between the vaginal
microbiota and HPV infection are mainly carried out during the
reproductive age. However, young women, especially teenagers,
constitute a high-risk group for HPV infection and studies have
shown a peak incidence at 21 years of age7. Vaginal microbiota
and related changes at an early stage of life may have more
fundamental effects during later life, such as oncogenic risk. Our
study is a large cross-sectional study of vaginal microbiota using
the sequencing method focused on young women (14–29 years).
Although our study lacks clinical data such as vaginal pH or data
on vaginal infections other than HPV, compared to other vaginal
microbiota studies, our study design limits the effect from
confounders such as the variability of hormone and immunity
levels due to a large age span. Further, this young group gives us a
unique group with high HPV infection prevalence7. The samples
from cervical screening, aged 23 years and above, have an HPV
prevalence of 34.1% (Supplementary Table 1). The two sample
sources are therefore combined to obtain a balanced HPV
infection cohort, to study the association between HPV infection
and vaginal microbiota. Nevertheless, most of the participants in
this study are Caucasian women. This allows us to limit
confounders by racioethnic diversity that may affect vaginal
microbiome18.
Studies have indicated that some of Lactobacillus species, such
as L. gasseri, may potentially be beneficial for HPV clearance14,25.
Recent findings suggest a possible association between certain
compositions of vaginal microbiota and HPV clearance or
progression to cervical dysplasia and cancer12,24,30,31. However,
although few longitudinal studies hint about how microbiota
might influence HPV persistent infection, HPV could also
contribute to the change of vaginal microbiota stability and
composition26,32. Moreover, a change in HPV infection and
vaginal microbiota may occur simultaneously due to sexual
activities. The potentially bi-directional effect needs to be
explored further. More studies, especially longitudinal ones, are
needed to help us understand which vaginal microbiota
composition is related to a higher risk of HPV infection, to
cervical dysplasia, and cancer development. Further, the under-
lying mechanisms for potential interaction between HPV and
microbiota need to be deciphered.
In conclusion, this is a large cross-sectional study on young
Swedish women with high HPV vaccination coverage. It demon-
strates the strong association between non-Lactobacillus-domi-
nated vaginal microbiota and HPV infection, including any HPV,
oncogenic HPV infection, and multiple HPV types. It also indicates
that HPV vaccine has little impact on vaginal microbiota, and
bacterial species such as BVABs could potentially be used as a
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METHODS
Study population
In total, 172 previously described young women and 34 new participants,
between the ages of 14 and 22, who visited a youth clinic in Stockholm
were included (n= 206)7. Their samples were collected during the clinical
visit either by clinical staff or self-collected with a vaginal swab
(FLOQSwabs™, Copan Flock Technologies, Brescia, Italy). Vaginal swab
was Inserted ~2–3 cm into the vagina and swirled for ~30 s. In addition,
139 study participants between 23 and 29 years were enrolled from the
population-based cervical screening at maternal health clinics (n= 133),
and from follow-up screening at the gynecological clinic, Uppsala
university hospital (n= 6), Uppsala, Sweden. These samples were collected
by clinical staff and referred to as the cervical screening samples. Collection
methods were compared prior to the study and showed no difference in
microbiota composition33. For all the samples, the collection swabs were
immediately put inside FluidX tubes (Brooks Life Sciences, Chelmsford, MA,
USA) containing 0.8 ml DNA/RNA-shield (Zymo Research, Irvine, CA, USA).
Information as to age, HPV vaccination status and antibiotic usage within
the past 3 months was ascertained from study participants. All
participation was voluntary and anonymized, and written informed
consent was obtained. This study was performed according to ethical
permission approved by the Stockholm Regional Ethics Committee and
Uppsala Regional Ethics Committee in Sweden.
DNA extraction
The collection fluid containing the vaginal microbiota was bead-beaten
with Matrix E beads (MP Biomedicals, USA), followed by digestion with
Proteinase K (20 µl of 20mg/ml proteinase K in Proteinase K Storage Buffer
for 90min, 55 °C, 250 rpm) and purification with magnetic beads according
to the manufacturer’s guidelines for the ZR-96 Genomic DNA MagPrep kit
(Zymo Research, USA), as previously described7,33. Owing to the large
sample size and long collection period, DNA extraction was conducted
using two versions of the ZR-96 Genomic DNA MagPrep kits. These two
versions are from product upgrades that were confirmed to produce
comparable microbiota results7,33. In each batch for DNA extraction, we
included collection fluid and Zymo Microbial Community DNA Standard
(Cat. no. D6300, Zymo Research, USA) as the negative and positive
extraction controls, respectively. The purified DNA was stored at −20 °C
until further HPV genotyping and microbiota sequencing.
HPV genotyping
DNA was polymerase chain reaction (PCR) amplified with broad-spectrum
GP5+/6+ primers targeting the HPV L1 region, as well as HPV16 and
HPV33 primers targeting the E6 region. The HPV16 E6 primers consist of
HPV16E6-Forward (TCAAAAGCCACTGTGTCCTGA), HPV16E6-3-Reverse
(GCTGGGTTTCTCTACGTGTTC). HPV33 E6 primers including HPV33E6-
Forward (TCGTTGGGCAGGGCGCTGTG), and HPV33E6-Reverse (CTCGTGTCC
TCTCATGGCGTT) as previously described34,35. The PCR conditions con-
tained initial denaturation at 94 °C for 15min, followed by 40 cycles of
denaturation at 94 °C for 30 s, annealing at 38 °C for 90 s and extension at
71 °C for 80 s, and a final extension step at 71 °C for 4 min. The PCR product
was further evaluated using a multiplex bead-based assay on a MAGPIX
instrument (Luminex Inc., USA), as reported previously4,7. Probes for
detecting HPV16 E6p (GTCTTGTTGCAGATCATCAAG) and HPV33E6p
(GAAACTGCACTGTGACGTGTA) were added34,35. Twenty-seven types of
HPV were analyzed, including fifteen oncogenic HPVs (HPV16, 18, 31, 33,
35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82), six probably oncogenic HPVs
(HPV26, 30, 53, 66, 67, 69), and six non-oncogenic HPVs (HPV6, 11, 42, 43,
44, 70)4,7.
Microbiota sequencing
The V3-V4 regions of the 16S rRNA genes were amplified from extracted
DNA with Illumina sequencing index-binding primer pairs 341F/805R, as
previously described33. For each batch of sample sequencing library
preparation, we included DNA-free water and Zymo Microbial Community
DNA Standard (Cat. no. D6305, Zymo Research, USA) as the negative and
positive PCR controls, respectively. Thereafter, the 16S amplicons indexed
from the samples and controls (including extraction and PCR controls) of
the same batch were pooled together in equal molar amounts and
subjected to an Illumina MiSeq sequencing platform (Illumina, CA, USA)
with MiSeq Reagent Kit v3.
Bioinformatics analysis
After base calling and de-multiplexing, the fastq files generated from each
run were subjected to quality trimming, de-noising, merging, and chimera
removal, before being processed into sequencing tables. The degenerated
primers were firstly trimmed off from the paired-end reads and a
preliminary quality trimming was then conducted with cutadapt (v. 2.0)
with the setting of minimum q value of 15, maximum N base of zero, and
minimum qualified read length of 12036. Thereafter, the processed reads
were sent to DADA2 pipeline (v. 1.13.1) for further quality trimming, de-
noising, merging, and chimera removal. In this step, the paired-end reads
that have more than two expected errors (maxEE= c(2,2)) or derived from
PhiX (rm.phix= TRUE) were discarded37. The low-quality tail from each
read was trimmed off to keep the mean q value >20 (truncLen= c (265,
200)). After DADA2 de-noising, the paired-end reads were merged with at
least a 30-bp overlap. Chimera checking was conducted on the merged
reads and the recovered ASVs were summarized and used to generate the
sequence table for the sequencing run. The sequencing content from the
sequencing library controls was used to assess the performance of each
sequencing run. Finally, all sequence tables of the qualified sequencing
runs were parsed into a total sample sequence table, by collapsing rows of
the identical ASVs from the raw sequence tables.
Decontamination
In order to remove the ASVs from sequencing backgrounds (e.g., reagent,
laboratory environment, etc.), a decontamination procedure was con-
ducted on the merged sequence table, containing both samples and
controls. As the substantial fraction of DNA from vaginal swab samples is
human DNA, we employed a combined method considering both
frequency and prevalence, to identify contaminant ASVs by using
Decontam (v. 1.1.2) on R38. ASVs that show positive correlation in their
reads fraction and DNA concentration in negative controls but not in
samples, and ASVs that have high prevalence in controls but not in
samples, were discarded. After the decontamination step, the controls
were excluded from the sequence table for downstream data analysis.
Sequence annotation
A preliminary classification was conducted in R by using DADA2 functions
“assignTaxonomy” and “addSpecies” to search ASVs against the Silva
database (v. 128)39. As Lactobacillus spp. are dominant in most of the
vaginal microbiota, we improved the classification of the ASVs annotated
as Lactobacillus by manually BLAST searching them in the National Center
for Biotechnology Information (NCBI) database40,41. Moreover, bacterial
vaginosis-associated bacteria (BVAB) 1, 2, and 3 were searched from ASVs
containing 16S primer-binding regions in the whole genomic sequences
and 16S sequences downloaded from other published works20–22,42–48. The
classification of ASVs was further validated by searching BVAB qPCR primer
sequences from the BVAB ASVs49. For the classification of Lactobacillus
species and BVAB, a maximum of one mismatch was allowed from the
alignment.
Phylogenetic tree construction
To facilitate the calculation of Faith’s diversity and UniFrac distance matrix
for the downstream analyses, a phylogenetic tree of the ASVs generated in
this study was constructed. A multi-alignment of all ASVs was firstly
conducted using MAFFT (v.7.407) with the default parameters. The
phylogeny was determined using FastTree2 (v.2.18). The generated tree
in newick format was then loaded to FigTree for visualization and double-
checking whether the phylogenies of the ASVs correspond to their
taxonomic annotations.
Alpha- and beta-diversity calculation
The sequence table was rarefied to 4902 reads per sample, before
conducting a diversity calculation in R by using the package “vegan” (v.
2.5-6). Alpha diversities (i.e., Shannon, Chao 1 and Faith’s phylogenetic
diversity) were calculated using the functions from the same package,
which were visualized in violin plots using the package “ggplot2” (v. 3.2.1).
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PCoA was conducted based on Bray-Curtis distance matrix and weighted
UniFrac distance matrix, using the package “phyloseq” (v. 1.26.1).
Statistics
To test the differences among microbial alpha diversities, the Wilcoxon
rank-sum test and Kruskal–Wallis test were employed when comparing
diversities between two groups and more than two groups, respectively.
Benjamini–Hochberg correction was conducted to decrease the false
discovery rate for multiple tests. The same test method was also
conducted to identify taxa that are significantly different in proportional
abundance between the cohorts. The association between microbiota
community structure and HPV, oncogenic HPV, or multiple HPV types was
analyzed by multivariable logistic regression, adjusted for age, HPV
vaccination status, sample source, and presented as OR and 95% CI, with
95% CI not including OR= 1, indicating statistically significant differences.
The relationship among HPV infection, vaginal microbiota, age, sample
source, and vaccination status were compared by Fisher’s exact test.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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